Skip to main content
. Author manuscript; available in PMC: 2023 Oct 19.
Published in final edited form as: Nat Rev Clin Oncol. 2022 Jun 20;19(8):534–550. doi: 10.1038/s41571-022-00652-y

Fig. 3 |. The predicted global nuclear medicine market 2013–2026.

Fig. 3 |

This projected market growth likely reflects the availability of a greater number of agents, implementation at an increasing number of centres and projected increases in the numbers of patients with cancer globally. ©MEDraysintell Nuclear Medicine Report C Directory, Edition 2021. CRPC, castration-resistant prostate cancer; mCRPC, metastatic CRPC; NET, neuroendocrine tumour; PSMA, prostate-specific membrane antigen.